Report
mRNA COVID Vaccines Show Promise Boosting Lung Cancer Immunotherapy
A Nature study found lung cancer patients receiving mRNA COVID-19 vaccines within ~100 days of starting immunotherapy had significantly better survival—median ~37 months vs. ~21 months. The vaccine's immune-priming appears to enhance anti-tumor immunity; similar signals observed in melanoma data.
TLDR
This finding suggests potential repurposing of widely administered vaccines to improve immunotherapy effectiveness against cancer, offering hope for patients and demonstrating unexpected synergies between distinct immune interventions—though the association awaits clinical trial confirmation.
Combined views
19.1K
1 Source, first seen 4h ago
162 likes12 comments28 saves44 reposts